175 related articles for article (PubMed ID: 34101386)
1. TDO2 overexpression correlates with poor prognosis, cancer stemness, and resistance to cetuximab in bladder cancer.
Pham QT; Taniyama D; Akabane S; Harada K; Babasaki T; Sekino Y; Hayashi T; Sakamoto N; Sentani K; Oue N; Yasui W
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1417. PubMed ID: 34101386
[TBL] [Abstract][Full Text] [Related]
2. TDO2 Overexpression Is Associated with Cancer Stem Cells and Poor Prognosis in Esophageal Squamous Cell Carcinoma.
Pham QT; Oue N; Sekino Y; Yamamoto Y; Shigematsu Y; Sakamoto N; Sentani K; Uraoka N; Yasui W
Oncology; 2018; 95(5):297-308. PubMed ID: 30134247
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic features of TDO2 overexpression in renal cell carcinoma.
Pham QT; Taniyama D; Sekino Y; Akabane S; Babasaki T; Kobayashi G; Sakamoto N; Sentani K; Oue N; Yasui W
BMC Cancer; 2021 Jun; 21(1):737. PubMed ID: 34174844
[TBL] [Abstract][Full Text] [Related]
4. Essential Roles of TDO2 in Gastric Cancer: TDO2 Is Associated with Cancer Progression, Patient Survival, PD-L1 Expression, and Cancer Stem Cells.
Pham QT; Taniyama D; Akabane S; Takashima T; Maruyama R; Sekino Y; Sentani K; Yasui W; Oue N
Pathobiology; 2023; 90(1):44-55. PubMed ID: 35679834
[TBL] [Abstract][Full Text] [Related]
5. TDO2 knockdown inhibits colorectal cancer progression via TDO2-KYNU-AhR pathway.
Zhao L; Wang B; Yang C; Lin Y; Zhang Z; Wang S; Ye Y; Shen Z
Gene; 2021 Aug; 792():145736. PubMed ID: 34051337
[TBL] [Abstract][Full Text] [Related]
6. Opa interacting protein 5 acts as an oncogene in bladder cancer.
He X; Hou J; Ping J; Wen D; He J
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2221-2233. PubMed ID: 28752236
[TBL] [Abstract][Full Text] [Related]
7. Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBPβ.
Kudo T; Prentzell MT; Mohapatra SR; Sahm F; Zhao Z; Grummt I; Wick W; Opitz CA; Platten M; Green EW
Front Immunol; 2020; 11():657. PubMed ID: 32477324
[TBL] [Abstract][Full Text] [Related]
8. Tryptophan 2, 3‑dioxygenase promotes proliferation, migration and invasion of ovarian cancer cells.
Zhao Y; Tao F; Jiang J; Chen L; Du J; Cheng X; He Q; Zhong S; Chen W; Wu X; Ou R; Xu Y; Tang KF
Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33846800
[TBL] [Abstract][Full Text] [Related]
9. Pancancer Analysis of Revealed
Cui J; Tian Y; Liu T; Lin X; Li L; Li Z; Shen L
Dis Markers; 2022; 2022():5447017. PubMed ID: 36118672
[TBL] [Abstract][Full Text] [Related]
10. TDO2 modulates liver cancer cell migration and invasion via the Wnt5a pathway.
Liu H; Xiang Y; Zong QB; Dai ZT; Wu H; Zhang HM; Huang Y; Shen C; Wang J; Lu ZX; Ponnambalam S; Chen K; Wu Y; Zhang TC; Liao XH
Int J Oncol; 2022 Jun; 60(6):. PubMed ID: 35475491
[TBL] [Abstract][Full Text] [Related]
11. Breakdown of chemo-immune resistance by a TDO2-targeted Pt(IV) prodrug via attenuating endogenous Kyn-AhR-AQP4 metabolic circuity and TLS-promoted genomic instability.
Chen F; Xu G; Tian W; Gou S
Biochem Pharmacol; 2021 Nov; 193():114785. PubMed ID: 34562469
[TBL] [Abstract][Full Text] [Related]
12. Circular RNA circZNF566 promotes hepatocellular carcinoma progression by sponging miR-4738-3p and regulating TDO2 expression.
Li S; Weng J; Song F; Li L; Xiao C; Yang W; Xu J
Cell Death Dis; 2020 Jun; 11(6):452. PubMed ID: 32532962
[TBL] [Abstract][Full Text] [Related]
13. TDO2 promotes bladder cancer progression via AhR-mediated SPARC/FILIP1L signaling.
Ding X; Jin Y; Shi X; Wang Y; Jin Z; Yin L; Gao S; Lei Y; Yang J
Biochem Pharmacol; 2024 May; 223():116172. PubMed ID: 38552852
[TBL] [Abstract][Full Text] [Related]
14. Predictive Value of CD44 in Muscle-Invasive Bladder Cancer and Its Relationship with IL-6 Signaling.
Wu CT; Lin WY; Chen WC; Chen MF
Ann Surg Oncol; 2018 Nov; 25(12):3518-3526. PubMed ID: 30128900
[TBL] [Abstract][Full Text] [Related]
15. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.
D'Amato NC; Rogers TJ; Gordon MA; Greene LI; Cochrane DR; Spoelstra NS; Nemkov TG; D'Alessandro A; Hansen KC; Richer JK
Cancer Res; 2015 Nov; 75(21):4651-64. PubMed ID: 26363006
[TBL] [Abstract][Full Text] [Related]
16. The Prognostic Value of Cancer Stem Cell Markers (Notch1, ALDH1, and CD44) in Primary Colorectal Carcinoma.
Mohamed SY; Kaf RM; Ahmed MM; Elwan A; Ashour HR; Ibrahim A
J Gastrointest Cancer; 2019 Dec; 50(4):824-837. PubMed ID: 30136202
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via the KRAS/MEK pathway in head and neck cancer.
Liu K; Hu H; Jiang H; Liu C; Zhang H; Gong S; Wei D; Yu Z
Mol Carcinog; 2020 Oct; 59(10):1147-1158. PubMed ID: 32805066
[TBL] [Abstract][Full Text] [Related]
18. Aldehyde dehydrogenase 1 (ALDH1) expression is associated with a poor prognosis of bladder cancer.
Xu N; Shao MM; Zhang HT; Jin MS; Dong Y; Ou RJ; Wang HM; Shi AP
Cancer Epidemiol; 2015 Jun; 39(3):375-81. PubMed ID: 25843691
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of CD44 variant 9 expression as a prognostic indicator in bladder cancer.
Kobayashi K; Matsumoto H; Matsuyama H; Fujii N; Inoue R; Yamamoto Y; Nagao K
Oncol Rep; 2016 Nov; 36(5):2852-2860. PubMed ID: 27599396
[TBL] [Abstract][Full Text] [Related]
20. Rac3 Expression and its Clinicopathological Significance in Patients With Bladder Cancer.
Chen M; Nie Z; Cao H; Gao Y; Wen X; Zhang C; Zhang S
Pathol Oncol Res; 2021; 27():598460. PubMed ID: 34257551
[No Abstract] [Full Text] [Related]
[Next] [New Search]
